Topics

Biogen Inc.: Biogen to Present New Interim Data from Its Phase 1/2 Clinical Study of Tofersen (BIIB067) for the Potential Treatment of a Subtype of Familial Amyotrophic Lateral Sclerosis (ALS)

16:41 EDT 1 May 2019 | FinanzNachrichten

Tofersen, an antisense oligonucleotide (ASO) that selectively targets the genetic driver of disease, is being studied for the potential treatment of ALS in adults with a confirmed superoxide dismut...

Original Article: Biogen Inc.: Biogen to Present New Interim Data from Its Phase 1/2 Clinical Study of Tofersen (BIIB067) for the Potential Treatment of a Subtype of Familial Amyotrophic Lateral Sclerosis (ALS)

NEXT ARTICLE

More From BioPortfolio on "Biogen Inc.: Biogen to Present New Interim Data from Its Phase 1/2 Clinical Study of Tofersen (BIIB067) for the Potential Treatment of a Subtype of Familial Amyotrophic Lateral Sclerosis (ALS)"

Quick Search

Relevant Topic

Antisense therapy
Most human diseases are caused by production of abnormal proteins or malfunctioning proteins.   Antisense therapy involves inhibiting production of these proteins.  When a gene is known to cause a specific disease and the genetic sequence ...